MyFinsight
Home
Blog
About
Contact
Download
Download image
Gross proceeds from
secondary public offering
$20,174K
Net cash provided by
financing activities
$19,569K
Canceled cashflow
$605K
Net increase
(decrease) in cash and cash...
$8,173K
Canceled cashflow
$11,396K
Commissions paid on
secondary public offering
$605K
Change in fair value of
warrant liability
$4,780K
Accounts payable and
accrued liabilities
$2,285K
Stock-based compensation
expense
$754K
Amortization of operating
lease right of use...
$203K
Loss on disposal of
assets
-$18K
Amortization of investments
in marketable...
$12K
Depreciation expense
$8K
Realized gain on
marketable securities
-$2K
Net cash used in
operating activities
-$6,241K
Net cash used in
investing activities
-$5,155K
Canceled cashflow
$8,060K
Canceled cashflow
$2K
Net income (loss)
-$12,823K
Purchases of marketable
securities
$5,149K
Purchases of property and
equipment
$8K
Prepaid expense and
other current assets
$1,267K
Operating lease liability
-$211K
Back
Back
Cash Flow
source: myfinsight.com
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)